Analysts Are Bullish on These Healthcare Stocks: GNCA, ASNS

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Genocea Biosciences (NASDAQ: GNCA) and Arsanis Inc (NASDAQ: ASNS) with bullish sentiments.

Genocea Biosciences (NASDAQ: GNCA)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Genocea Biosciences (NASDAQ: GNCA), with a price target of $5. The company’s shares opened today at $0.91, close to its 52-week low of $0.79.

According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -13.0% and a 34.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.

Genocea Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $4.

See today’s analyst top recommended stocks >>

Arsanis Inc (NASDAQ: ASNS)

Cantor Fitzgerald analyst Louise Chen reiterated a Buy rating on Arsanis Inc (NASDAQ: ASNS) today and set a price target of $26. The company’s shares opened today at $19.91.

Chen noted:

“Takeaways from this quarter that support our thesis: 1) On 03/14/18, ASNS announced that the USPTO issued U.S. Patent No. 9914767 to the company. This patent broadly claims composition of matter for antibodies that cross-neutralize Staphylococcus aureus alpha hemolysin (Hla) and up to four additional S. aureus leukocidins targeted by ASN-1, one of the two antibodies in the company’s lead product candidate, ASN100. This patent grants intellectual property protection in the U.S. through 2033, 2) ASNS entered into an agreement under which a subsidiary of Bravos Biosciences (Private) has secured an exclusive, worldwide preclinical development license, and an option to a clinical development and commercialization license, to mAbs targeting E.”

According to TipRanks.com, Chen has currently no stars on a ranking scale of 0-5 stars, with an average return of -10.3% and a 37.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Paratek Pharmaceuticals, and Spero Therapeutics Inc.

Arsanis Inc has an analyst consensus of Strong Buy, with a price target consensus of $24.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.